Trade-Ideas: TG Therapeutics (TGTX) Is Today's Strong On High Relative Volume Stock
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.
Trade-Ideas LLC identified
(
) as a strong on high relative volume candidate. In addition to specific proprietary factors, Trade-Ideas identified TG Therapeutics as such a stock due to the following factors:
- TGTX has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $7.9 million.
- TGTX has traded 60,255 shares today.
- TGTX is trading at 2.05 times the normal volume for the stock at this time of day.
- TGTX is trading at a new high 4.13% above yesterday's close.
'Strong on High Relative Volume' stocks are worth watching because major volume moves tend to indicate underlying activity such as M&A events, material stock news, analyst upgrades, insider buying, buying from 'superinvestors,' or that hedge funds and momentum traders are piling into a stock ahead of a catalyst. Regardless of the impetus behind the price and volume action, when a stock moves with strength and volume it can indicate the start of a new trend on which early investors can capitalize. In the event of a well-timed trading opportunity, combining technical indicators with fundamental trends and a disciplined trading methodology should help you take the first steps towards investment success.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in TGTX with the Ticky from Trade-Ideas. See the FREE profile for TGTX NOW at Trade-Ideas
More details on TGTX:
TG Therapeutics, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of various pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. Currently there are 4 analysts that rate TG Therapeutics a buy, no analysts rate it a sell, and none rate it a hold.
The average volume for TG Therapeutics has been 549,800 shares per day over the past 30 days. TG has a market cap of $703.4 million and is part of the health care sector and drugs industry. The stock has a beta of -0.80 and a short float of 12.6% with 6.19 days to cover. Shares are up 0.9% year-to-date as of the close of trading on Thursday.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Analysis:
rates TG Therapeutics as a
. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity and feeble growth in its earnings per share.
Highlights from the ratings report include:
- The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Biotechnology industry. The net income has significantly decreased by 231.8% when compared to the same quarter one year ago, falling from -$5.66 million to -$18.80 million.
- Return on equity has greatly decreased when compared to its ROE from the same quarter one year prior. This is a signal of major weakness within the corporation. Compared to other companies in the Biotechnology industry and the overall market, TG THERAPEUTICS INC's return on equity significantly trails that of both the industry average and the S&P 500.
- TG THERAPEUTICS INC has experienced a steep decline in earnings per share in the most recent quarter in comparison to its performance from the same quarter a year ago. The company has reported a trend of declining earnings per share over the past year. However, the consensus estimate suggests that this trend should reverse in the coming year. During the past fiscal year, TG THERAPEUTICS INC reported poor results of -$1.60 versus -$0.81 in the prior year. This year, the market expects an improvement in earnings (-$1.12 versus -$1.60).
- The revenue growth greatly trails the industry average of 36.3%. Since the same quarter one year prior, revenues have remained constant. Even though the company's revenue remained stagnant, the earnings per share decreased.
- Compared to its closing price of one year ago, TGTX's share price has jumped by 138.45%, exceeding the performance of the broader market during that same time frame. Regarding the future course of this stock, we feel that the risks involved in investing in TGTX do not compensate for any future upside potential, despite the fact that it has seen nice gains over the past 12 months.
- You can view the full TG Therapeutics Ratings Report.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
null